Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $4.11, down 0.96% on the session, giving a market capitalisation of $292.6M. On trailing twelve-month figures it carries a trailing P/E of -1.67, a net margin of 0.0%. Its beta of 1.89 implies it has historically moved more than the broad market.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Zentalis Pharmaceuticals, Inc. is most often compared with the following Healthcare names: